IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 2, 2009, Pages 205-213

  Nevill, Thomas J ^a   Shepherd, John D ^a   Sutherland, Heather J ^a   Abou Mourad, Yasser R ^a   Lavoie, Julye C ^a   Barnett, Michael J ^a   Nantel, Stephen H ^a   Toze, Cynthia L ^a   Hogge, Donna E ^a   Forrest, Donna L ^a   Song, Kevin W ^a   Power, Maryse M ^a   Nitta, Janet Y ^a   Dai, Yunfeng ^a   Smith, Clayton A ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Blood stem cell transplantation; Myelodysplastic syndrome; Poor risk karyotype

Indexed keywords

BUSULFAN; CYCLOSPORIN; CYTARABINE; DACLIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; INOLIMOMAB; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; XOMAZYME;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHROMOSOME ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PREDICTION; PROGNOSIS; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYTOGENETIC ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58649122895     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.015     Document Type: Article

References (47)

1. Cazzola M., and Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352 (2005) 536-538
2. Anderson J.E., Appelbaum F.R., and Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 17 (1995) 95-99
3. O'Donnell M.R., Long G.D., Parker P.M., et al. Busulfan/cyclophosphamide as conditioning regimen fior allogeneic bonwe marrow transplantation for myelodysplasia. J Clin Oncol 13 (1995) 2973-2979
4. Sutton L., Chasteng C., Ribaud P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 88 (1996) 358-365
5. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndromes are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92 (1997) 1910-1917
6. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Boner Marrow Transplatation. Br J Haematol 110 (2000) 620-630
7. Sierra J., Pérez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
8. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
9. Bensinger W.I., Weaver C.H., Appelbaum F.R., et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 856 (1995) 1655-1658
10. Schmitz N., Dreger P., Suttorp M., et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85 (1995) 1666-1672
11. Korbling M., Przepiorka H.Y.O., et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85 (1995) 1659-1665
12. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95 (2000) 3702-3709
13. Powles R., Mehta J., Kulkarni S., et al. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomized trial. Lancet 355 (2000) 1231-1237
14. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
15. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002) 1525-1531
16. Storek J., Gooley T., Siadak M., et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90 (1997) 4705-4709
17. Przepiorka D., Anderlini P., Saliba R., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98 (2001) 1695-1700
18. Garderet L., Labpin M., Gorin N.C., et al. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 31 (2003) 23-29
19. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 13 (2007) 1461-1468
20. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
21. Ringdén O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94 (1999) 455-464
22. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
23. Grigg A., Shepherd J.D., and Phillips G.L. Busulphan and phenytoin. Ann Intern Med 111 (1989) 1049-1050
24. Shepherd J.D., Pringle L.E., Barnett M.J., et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9 (1991) 2016-2020
25. Attal M., Huguet F., Rubie H., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion low-dose heparin: a prospective, randomized trial. Blood 79 (1992) 2834-2840
26. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
27. Thomas T.E., Abraham S.J.R., Phillips G.L., and Lansdorp P.E. Depletion of CD3+ cells from allogeneic bone marrow grafts using high gradient magnetic separation. Clin Invest Med 17 Suppl B (1994) 58
28. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in hman recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
29. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
30. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
31. Gray J.R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
32. Latouche A., Porcher R., and Chevret S. A note on including time-dependent covariate in regression model for competing risks data. Biometrics 47 (2005) 807-814
33. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
34. Appelbaum F.R., and Anderson J. Allogeneic marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 Suppl 1 (1998) 25-29
35. Russell J.A., Larratt L., Brown C., et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 24 (1999) 1177-1183
36. Guardiola P., Runde V., Bacigalupo, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99 (2002) 4370-4378
37. del Cañizo M.C., Martínez C., Conde E., et al. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 32 (2003) 987-992
38. Remberger M., Ringdén O., Blau I.-W., et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral blood stem cells to bone marrow using unrelated donors. Blood 98 (2001) 1739-1745
39. Elmaagacli A.H., Basoglu S., Peceny R., et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99 (2002) 1130-1135
40. Yakoub-Agha I., de La Salmoniére P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18 (2000) 963-971
41. Scott B.L., Storer B., Loken M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 65-73
42. Martino R., Caballero M.D., Pérez Simón J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
43. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
44. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
45. Shimoni A Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
46. Kröger N., Bornhäuser M., Ehninger G., et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82 (2003) 336-342
47. Lim Z.Y., Ho A.Y.L., Ingram W., et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135 (2006) 201-209